– Interventional Radiologist, Tumor Ablation China
Future trends such as immunotherapy used in combination with ablation technologies is gaining prominence. Acceptance of tumor ablation to treat cancer types such as breast cancer is expected to increase as clinical evidence suggests good patient outcomes.
Competitor landscape covers market events such as emerging companies, product approvals, clinical trials, partnerships etc. Competitor activities such IceCure MedTech Co. Ltd signed an exclusive distribution agreement for IceSense3 (ProSense’s brand name in China) cryoablation systems with Shanghai Medtronic Zhikang Medical Devices Co. Ltd., an affiliate of Medtronic plc and Beijing Turing Medical Technology Co. Ltd.; Information on Ethicon Inc (J&J) conducting an interventional clinical trial to evaluate the effectiveness and safety of NeuWave Certus microwave ablation system (MWA) in Chinese patients with primary and secondary tumors in lung are covered in the report..